Antithrombotic Activity of a Newly Synthesized Coumarin Derivative 3-(5-Hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide

Manish Jain, William R. Surin, Ankita Misra, Prem Prakash, Vishal Singh, Vivek Khanna, Satish Kumar, Hefazat H. Siddiqui, Kanwal Raj, Manoj K. Barthwal, Madhu Dikshit

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Anti-platelet therapy is a useful strategy to prevent acute thromboembolic artery occlusions. This study was designed to assess the efficacy of seselin derivatives against murine pulmonary thromboembolism, bleeding time, platelet activation and thrombosis. Administration of C3 (16mg/kg) offered 70% protection against collagen- and epinephrine-induced pulmonary thromboembolism and 30% protection against arachidonic acid-induced death in mice, without adversely affecting bleeding time. No significant difference was observed by C3 in ferric chloride-induced arterial thrombosis in rats. Significant reduction in thrombus weight was observed in arteriovenous shunt model. In rat PRP, C3 reduced ADP and collagen-induced platelet aggregation. In chronic hamster model of dyslipidemia, administration of C3 (16mg/kg p.o. for 90days) had no effect on plasma lipids, vasoreactivity and platelet adhesion. C3 fed hamsters showed reduced whole-blood aggregation response to ADP and collagen compared to HC-fed hamsters. In addition, C3 augmented thrombin time; however, time to occlusion was not increased. These results convincingly demonstrated that C3 is a novel molecule that reduces the risk of thrombosis and alleviates prothrombotic state associated with hyperlipidemia without any adverse effect on bleeding time. The high benefit/risk ratio of this compound makes it a suitable candidate for future valid studies. Coumarin derivatives [C3] demonstrated antithrombotic efficacy without any adverse effect on bleeding time. Mode of antithrombotic action of C3 seems to be due to anti-platelet activity and to a certain extent by anti-coagulant mechanisms. Relationship among effects on clotting times, anti-thrombotic efficacy, and bleeding risk with C3 must be established in clinical trials.

Original languageEnglish (US)
Pages (from-to)499-508
Number of pages10
JournalChemical Biology and Drug Design
Issue number4
StatePublished - Apr 2013

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Antithrombotic Activity of a Newly Synthesized Coumarin Derivative 3-(5-Hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide'. Together they form a unique fingerprint.

Cite this